Đang chuẩn bị liên kết để tải về tài liệu:
Báo cáo y học: "Anti-Xa activity after subcutaneous administration of dalteparin in ICU patients with and without subcutaneous oedema: a pilot study"

Tuyển tập các báo cáo nghiên cứu về y học được đăng trên tạp chí y học Critical Care cung cấp cho các bạn kiến thức về ngành y đề tài: Anti-Xa activity after subcutaneous administration of dalteparin in ICU patients with and without subcutaneous oedema: a pilot study. | Available online http ccforum.eom content 10 3 R93 Open Access Research Anti-Xa activity after subcutaneous administration of dalteparin in ICU patients with and without subcutaneous oedema a pilot study Mirjam K Rommers1 2 Netty Van Der Lely3 Toine CG Egberts1 4 and Patricia MLA van den Bemt1 4 Hospital Pharmacy Midden-Brabant TweeSteden Hospital and St Elisabeth Hospital Tilburg the Netherlands 2Department of Clinical Pharmacy and Toxicology Leiden University Medical Centre Leiden the Netherlands 3Department of Intensive Care St Elisabeth Hospital Tilburg the Netherlands 4Department of Pharmaco-epidemiology and Pharmacotherapy Utrecht Institute for Pharmaceutical Sciences Utrecht University the Netherlands Corresponding author Mirjam K Rommers m.k.rommers@lumc.nl Received 22 Mar 2006 Revisions requested 20 Apr 2006 Revisions received 5 May 2006 Accepted 18 May 2006 Published 21 Jun 2006 Critical Care 2006 10 R93 doi 10.1186 cc4952 This article is online at http ccforum.com content 10 3 R93 2006 Rommers et al. licensee BioMed Central Ltd. This is an open access article distributed under the terms of the Creative Commons Attribution License http creativecommons.org licenses by 2.0 which permits unrestricted use distribution and reproduction in any medium provided the original work is properly cited. Abstract Introduction Intensive care unit ICU patients often suffer from subcutaneous oedema due to administration of large fluid volumes and the underlying pathophysiological condition. It is unknown whether the presence of subcutaneous oedema impairs the absorption of dalteparin a low molecular weight heparin when it is given by subcutaneous administration for venous thromboembolism prophylaxis. The objective of this study is to compare the anti-Xa activity of dalteparin after subcutaneous administration in ICU patients with and without subcutaneous oedema. Methods This non-randomized open parallel group follow-up pilot study was conducted in two mixed .